Ovid Therapeutics reported Q4 2025 earnings, posting earnings per share of $0.06 versus a consensus estimate of –$0.11, a beat of 152.63%. Revenue for the quarter totaled $0.7 million, exceeding consensus estimates by roughly 195%. The earnings beat reflects disciplined cost management and a favorable mix of revenue sources, including a one‑time royalty payment that boosted top‑line figures while operating expenses remained controlled.
Revenue was driven by a $7 million royalty payment and modest sales of the next‑generation GABA‑AT inhibitor OV329. The royalty inflow lifted revenue, and the company’s operating costs were kept in check, allowing it to post a positive net income for the quarter.
The company also closed a $60 million private placement on March 17 2026, with closing expected by March 19. The infusion expands the capital base to support expansion of OV329 into new indications and to fund first‑in‑human studies of OV4071, a KCC2 activator.
Clinical data for OV329 showed favorable safety and tolerability in the 7 mg cohort, reinforcing its potential for drug‑resistant epilepsy. Ovid announced plans to broaden OV329 development to tuberous sclerosis complex seizures and infantile spasms, while OV4071 cleared regulatory approval to begin Phase 1 trials.
President and CEO Meg Alexander said the results demonstrate the strength of Ovid’s scientific approach and the company’s ability to maintain a steady cadence of milestones, positioning the firm to deliver progress for patients and value for stakeholders.
Net income for the quarter was $9.7 million, largely driven by a $21 million gain on the fair‑value adjustment of a long‑term equity investment. The company’s full‑year 2025 loss narrowed to $17.4 million from $26.4 million in 2024, reflecting improved operating performance and the impact of the investment gain.
With $90.4 million in cash, cash equivalents, and marketable securities as of December 31 2025, and the new capital infusion, Ovid’s cash runway is projected to extend into late 2028, providing a buffer for ongoing clinical development and potential future milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.